The specific serotonin receptor blocker ketanserin was given orally to 12 patients with traumatic vasospastic disease in a double blind crossover study. The effect of treatment was assessed by measuring finger systolic pressure and rewarming time after cold provocation and by medical interview and diaries. Median (range) percentage change in finger systolic pressure after cooling was 50 (0-100)% after treatment with ketanserin compared with 0 (0-90)% after placebo. Median (range) rewarming time after cooling decreased from 320 (236-972)s with placebo to 160 (88-404)s after treatment with ketanserin. These changes were not significant. Ninety five percent confidence intervals for difference between the treatments, however, showed that finger systolic pressure may be 80% better and rewarming time 256 seconds faster after treatment with ketanserin than after placebo. The number of attacks did not differ significantly between the two treatments. Two patients had a feeling of warmth in their hands during treatment with ketanserin.
receptor.' The S2 receptor is selectively blocked by ketanserin. Through blocking the S2 receptor ketanserin antagonises vasoconstriction, blood platelet aggregation, and bronchoconstriction.' 2 Many early reports of treatment with ketanserin in patients with Raynaud's syndrome produced promising results.3 '5 In most trials the study population consisted of patients with syndromes of mixed aetiologies. Raynaud's syndrome of occupational origin, or traumatic vasospastic disease, develops in many workers after using vibrating tools for several years. Frequent attacks of pallor and deadness in the fingers prevent the worker from doing his job, especially during the winter. Improvement in the circulation of the fingers by medical treatment would thus be of special importance during this season. During the winter of 1983-4 we studied the effect of ketanserin in patients with traumatic vasospastic disease.
Patients and methods
Twelve men with traumatic vasospastic disease were studied. Nine were employed as welders in the same ship building factory, using pneumatic drills, chisels, and grinding machines for preparing and attaching iron plates. Two men were employed removing automobile brake linings using pneumatic chisels. One cabinet maker, who had been exposed to vibrations from saws, planes, and milling machines during every working day for 24 years, had changed to another job just before he was tested. The median age was 43 years (range 29-62), height 180 cm (range , and weight 83 kg (56-93). The median time before the development of symptoms was 12 years (range 2-20), and the median total time exposed to vibrating tools was 17 years (range . Except for disorders of their fingers, all patients were healthy. According to their own reports they were normally temperate in their consumption of alcohol. Eight of the 12 patients were smokers.
The investigation was carried out in accordance with the Helsinki II declaration, and all patients gave informed consent to join the study, which was approved by the local ethical committee.
The study was conducted as a double blind, fixed sample size trial with cross over. After two weeks' treatment with placebo the 12 patients were allocated by random number to receive either placebo or ketanserin for five weeks. This was followed by a second five week period with the opposite treatment. The dosage of ketanserin was 20 mg three times daily for the first week followed by four weeks at 40 mg three times daily. Tablets were identical in appearance, and changes in dosage were unknown to patients. The 10 were the values in the reference finger when the test finger was cooled to 30'C and 10'C respectively, and the bracketed term in the formula served as a correction for changes in systemic blood pressure.
The temperature of the finger was monitored by a skin sensor (Type A-H4, El-Lab) placed between the finger and the cuff and connected to a potentiometer (Type du 3s, El-Lab), from which a temperature curve was recorded on the recorder of the plethysmograph. Rewarming time was defined as the time from cessation of cooling for 5 minutes at 10C until the finger temperature had risen to 20'C.
In addition to a history typical of traumatic vasospastic disease, a requirement for entry into the study was that arterial spasms could be demonstrated objectively-that is, finger systolic pressure after cooling was zero.
At the end of each stage of the study serum creatinine and urea concentrations were measured to monitor kidney function, and alanine aminotransferase, aspartate aminotransferase, and lactate dehydrogenase 650 activities and albumin, cholesterol, and bilirubin concentrations were measured to assess liver function. As a test of compliance plasma concentrations of ketanserin were determined by high pressure liquid chromatography after treatment with the drug. Power of the tests and trial numbers have been calculated using the mean difference and standard error of difference.7
None of the patients found the benefit of the treatment so convincing that they wanted to continue after the end of the trial.
No changes in liver or kidney function were found after treatment with ketanserin.
Discussion
Traumatic vasospastic disease is difficult to diagnose between attacks. Because a typical history of disease was required for entry into this study, as well as occlusion at cold provocation, we believe that the risk of including subjects without the disease was small. Before the placebo run in period 11 of the 12 patients showed arterial spasms in response to different degrees of local cooling alone, whereas in one patient (case 3) spasms could be produced only after additional cooling ofthe arm in ice water for five minutes.
The lack of a significant difference between the treatments does not mean that a true difference did not exist (type II error). Especially when the sample size is small, the risk of not observing a true difference is considerable.910 The 95% confidence intervals assessed the uncertainty of the difference in the medians as the true effect of treatment. To calculate the power of the test the mean difference and standard error of difference were calculated' (table  III) . The probability of observing the present mean difference as significant (power of the test) with 11 patients in the study was 54% in the finger systolic pressure test and 34% in the rewarming time test. Conventionally, 90/o power ofthe test is required, and to reach this probability future studies will have to include 28 and 40 patients respectively.
Rewarming time was shown to be an appropriate test in traumatic vasospastic disease in a study in which the whole hand was cooled." We used local digital cooling because we considered it important not to provoke severe arterial spasms if a difference between ketanserin and placebo were to be detectable. In this study sevenof 11 patients had decreased rewarming times-after-treatment with ketanserin, which is consistent with improved skin perfusion found in other studies2 and with the feeling ofwarmth-in the hands reported by two patients.
Plasma concentrations of ketanserin were compared with known pharmacokinetic plasma decay curves, and in 11 and 12 cases values were in a range consistent with reasonable compliance. The plasma sample from one patient (case 4) taken three hours after the last stated consumption of medicine had no detectable ketanserin. During the treatment period, however, he had suffered from adverse reactions consistent with ketanserin, which suggests that he had previously taken his drugs. The patient (case 8) with the highest plasma concentration of ketanserin, at least twice the expected value, refused to continue into the second treatment period, having experienced intolerable restlessness, headache, and sluggishness during the first five week period. As with two other patients, he had a feeling of warmth in his hands after treatment.
The main side effects were itching and headache, and, except in case 8, the complaints were of only mild inconvenience. The overall incidence of side efifects was 36% in patients taking placebo and 54% in those taking ketanserin; this compares with 17% and 24% respectively among 206 patients collected from previous double blind studies.' As itching was not mentioned in these earlier studies, this probably accounts for the higher overall incidence in our study.
Diaries and interviews provided little evidence for any difference between the two treatments. In three cases the diaries could not be assessed because record keeping was incomplete, erratic, or idiosyncratic. In the remaining sets ofevaluable diaries evidence for activity in one period over another was never overwhelming. This was consistent with the patients' subjective perception of no noticeable difference.
Although the absence of subjective improvement and significant changes in cold provocation tests may reflect too small a study, the lack of improvement may, on the other hand, be explained by the nature of the disease. The intimal and muscular hypertrophy of the arteries in traumatic vasospastic disease'2 need longer periods of treatment to. improve to an extent that is clinically detectable. The vibrations may, however, have caused su'ch widespread destruction that ketanserin will not be able to reverse the circulatory injury.
Many vasoactive drugs have been tried in Raynaud's phenomenon.'3 These drugs are generally characterised by limited effect and the inevitable appearance of side effects. It appears that to limit the disabling effects of traumatic vasospastic disease preventive work is still of major importance. Improvements in the work environment, including reduction of vibration, cold, and time maintained handgrip, must continue to be our goal.
